Regeneron Pharmaceuticals, Inc.
Close on Nov 18, 2026Market cap $97.81BP/E 20.9Yield –
Total Accounts Receivable, Net của Regeneron Pharmaceuticals theo quý
Total Accounts Receivable, Net ($M) ($M)
Total Accounts Receivable, Net của Regeneron Pharmaceuticals: $7,579M trong Q3 2026, tăng 33.3% so với cùng kỳ năm trước. Đó là mức cao nhất trong 67 quý có ở đây.
Số của Q3 2026 lấy từ đâu
Nguồn: Form 10-Q (filed 2026-10-30) ↗
Được báo cáo trong Form 10-Q / 10-K Consolidated Balance Sheets & Concentration Note.
Lịch sử theo quý
Rê chuột vào một số để xem câu chữ đã đọc ra số đó; số tự tính sẽ hiện công thức
| Kỳ | Kết thúc | Total Accounts Receivable, Net ($M) ($M) | So với cùng kỳ | Nguồn |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 7,579 | +33.3% | Form 10-Q (filed 2026-10-30) ↗ |
| Q2 2026 | Jun 30, 2026 | 6,565 | +17.0% | Form 10-Q (filed 2026-07-30) ↗ |
| Q1 2026 | Mar 31, 2026 | 5,731 | +3.1% | Form 10-Q (filed 2026-04-29) ↗ |
| Q4 2025 | Dec 31, 2025 | 5,741 | -7.6% | Form 10-Q (filed 2026-10-30) ↗ |
| Q3 2025 | Sep 30, 2025 | 5,687 | -6.9% | Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2025 | Jun 30, 2025 | 5,610 | -1.9% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 5,561 | +6.5% | Form 10-Q (filed 2025-04-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 6,212 | +9.6% | Form 10-K (filed 2026-02-04) ↗ |
| Q3 2024 | Sep 30, 2024 | 6,107 | +9.4% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2024 | Jun 30, 2024 | 5,717 | +11.6% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 5,222 | +2.0% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,667 | +6.4% | Form 10-K (filed 2025-02-05) ↗ |
| Q3 2023 | Sep 30, 2023 | 5,585 | +0.7% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 5,121 | -0.8% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 5,119 | +5.8% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 5,329 | -11.7% | Form 10-K (filed 2024-02-05) ↗ |
| Q3 2022 | Sep 30, 2022 | 5,548 | +1.8% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 5,161 | -26.3% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 4,839 | +16.0% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 6,037 | +46.7% | Form 10-K (filed 2023-02-06) ↗ |
| Q3 2021 | Sep 30, 2021 | 5,452 | +76.3% | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 6,999 | +251.5% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 4,173 | +102.3% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 4,115 | +95.9% | Form 10-K (filed 2022-02-07) ↗ |
| Q3 2020 | Sep 30, 2020 | 3,093 | +52.5% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 1,991 | +3.7% | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 2,063 | +19.4% | Form 10-Q (filed 2020-05-05) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,100 | +21.8% | Form 10-K (filed 2021-02-08) ↗ |
| Q3 2019 | Sep 30, 2019 | 2,028 | +21.7% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,920 | +25.2% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,728 | +12.8% | Form 10-Q (filed 2019-05-07) ↗ |
| Q4 2018 | Dec 31, 2018 | 1,724 | +12.0% | Form 10-K (filed 2020-02-07) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,666 | +8.7% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,534 | +8.0% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,532 | +14.3% | Form 10-Q (filed 2018-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,539 | +14.5% | Form 10-K (filed 2019-02-07) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,533 | +15.1% | 10-Q FY2017 (XBRL) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,420 | -0.8% | 10-Q FY2017 (XBRL) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,340 | -7.6% | 10-Q FY2017 (XBRL) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,343 | +16.6% | Form 10-K (filed 2018-02-08) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,332 | +22.4% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,432 | +33.6% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,451 | +42.8% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,153 | +55.9% | Form 10-K (filed 2017-02-09) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,088 | +61.5% | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 1,072 | +61.4% | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 1,016 | +26.7% | 10-Q FY2015 (XBRL) ↗ |
| Q4 2014 | Dec 31, 2014 | 739 | -6.1% | Form 10-K (filed 2015-02-12) ↗ |
| Q3 2014 | Sep 30, 2014 | 674 | -21.3% | Form 10-Q (filed 2014-11-04) ↗ |
| Q2 2014 | Jun 30, 2014 | 664 | -13.5% | Form 10-Q (filed 2014-08-05) ↗ |
| Q1 2014 | Mar 31, 2014 | 802 | +13.9% | Form 10-Q (filed 2014-05-08) ↗ |
| Q4 2013 | Dec 31, 2013 | 787 | +32.7% | Form 10-K (filed 2014-02-13) ↗ |
| Q3 2013 | Sep 30, 2013 | 856 | +68.9% | Form 10-Q (filed 2013-11-05) ↗ |
| Q2 2013 | Jun 30, 2013 | 768 | +119.7% | Form 10-Q (filed 2013-08-06) ↗ |
| Q1 2013 | Mar 31, 2013 | 704 | +341.3% | Form 10-Q (filed 2013-05-03) ↗ |
| Q4 2012 | Dec 31, 2012 | 593 | +1,996.1% | Form 10-K (filed 2013-02-15) ↗ |
| Q3 2012 | Sep 30, 2012 | 507 | +13,594.6% | Form 10-Q (filed 2012-10-24) ↗ |
| Q2 2012 | Jun 30, 2012 | 350 | +11,955.2% | Form 10-Q (filed 2012-07-25) ↗ |
| Q1 2012 | Mar 31, 2012 | 160 | +4,097.4% | Form 10-Q (filed 2012-04-26) ↗ |
| Q4 2011 | Dec 31, 2011 | 28.3 | +1,130.4% | Form 10-K (filed 2012-02-21) ↗ |
| Q3 2011 | Sep 30, 2011 | 3.70 | +23.3% | Form 10-Q (filed 2011-10-27) ↗ |
| Q2 2011 | Jun 30, 2011 | 2.90 | -29.3% | Form 10-Q (filed 2011-07-28) ↗ |
| Q1 2011 | Mar 31, 2011 | 3.80 | – | Form 10-Q (filed 2011-05-03) ↗ |
| Q4 2010 | Dec 31, 2010 | 2.30 | -20.7% | Form 10-K (filed 2012-02-21) ↗ |
| Q3 2010 | Sep 30, 2010 | 3 | – | Form 10-Q (filed 2010-10-28) ↗ |
| Q2 2010 | Jun 30, 2010 | 4.10 | – | Form 10-Q (filed 2010-07-28) ↗ |
| Q4 2009 | Dec 31, 2009 | 2.90 | – | Form 10-Q (filed 2010-07-28) ↗ |
Phân tách
total Accounts Receivable, Net gồm những gì
- Trade Accounts Receivable, Net ($M)4,132 · Q3 2026
- Customer Revenue Concentration — Besse Medical (Cencora) Share of Gross Product Revenue (%)4,800.0% · Q3 2026
- Customer Revenue Concentration — McKesson Corporation Share of Gross Product Revenue (%)3,000.0% · Q3 2026
- Customer Accounts Receivable Concentration — Top Specialty Distributors Share of Trade AR [annual] (%)–
Trích dẫn dữ liệu này
StockData. (2026). Total Accounts Receivable, Net ($M) của Regeneron Pharmaceuticals, theo quý Q4 2009–Q3 2026 [Bộ dữ liệu]. Tổng hợp từ Hồ sơ SEC và tài liệu dành cho nhà đầu tư của Regeneron Pharmaceuticals. https://stockdatahq.com/stocks/regn/kpis/ar-total
Xem mọi chỉ số ở bảng KPI của Regeneron Pharmaceuticals. Dữ liệu cập nhật Nov 4, 2026.
See a number that looks wrong?